205 related articles for article (PubMed ID: 22334621)
21. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B
World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
[TBL] [Abstract][Full Text] [Related]
23. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
24. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
Golubchik P; Sever J; Zalsman G; Weizman A
Int Clin Psychopharmacol; 2008 Jul; 23(4):228-31. PubMed ID: 18446088
[TBL] [Abstract][Full Text] [Related]
25. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
[TBL] [Abstract][Full Text] [Related]
26. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
[TBL] [Abstract][Full Text] [Related]
27. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
McBurnett K; Starr HL
Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
[TBL] [Abstract][Full Text] [Related]
29. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Starr HL; Kemner J
J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
[TBL] [Abstract][Full Text] [Related]
30. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
[TBL] [Abstract][Full Text] [Related]
31. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study.
Wilens T; McBurnett K; Stein M; Lerner M; Spencer T; Wolraich M
J Am Acad Child Adolesc Psychiatry; 2005 Oct; 44(10):1015-23. PubMed ID: 16175106
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
33. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.
Adler LA; Orman C; Starr HL; Silber S; Palumbo J; Cooper K; Berwaerts J; Harrison DD
J Clin Psychopharmacol; 2011 Feb; 31(1):108-14. PubMed ID: 21192153
[TBL] [Abstract][Full Text] [Related]
36. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
[TBL] [Abstract][Full Text] [Related]
38. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
Buitelaar JK; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; Casas M; van Oene JC; Schäuble B; Trott GE
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):554-60. PubMed ID: 21185347
[TBL] [Abstract][Full Text] [Related]
39. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment.
Gürkan K; Bilgiç A; Türkoglu S; Kiliç BG; Aysev A; Uslu R
J Psychopharmacol; 2010 Dec; 24(12):1810-8. PubMed ID: 19939861
[TBL] [Abstract][Full Text] [Related]
40. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder.
Kim HW; Yoon IY; Cho SC; Kim BN; Chung S; Lee H; Kim CW; Park SK; Yoo HJ
Int Clin Psychopharmacol; 2010 Mar; 25(2):107-15. PubMed ID: 20093941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]